Here are five highlights:
1. Julian Panés, head of the gastroenterology department at the Hospital Clinic of Barcelona in Spain and chairman of the TiGenix ADMIRE-CD Scientific Advisory Board in Europe, will present the results.
2. In the double-blind, placebo controlled, randomized study, Cx601 met the primary endpoint of combined remission of complex perianal fistulas at week 24.
3. This is the first ever positive Phase III trial with an allogeneic stem cell product.
4. TiGenix submitted a Marketing Authorization Application for Cx601 in the first quarter of 2016 to the European Medicines Agency and expects to begin marketing the product in European markets in the second half of 2017.
5. Headquartered in Belgium, TiGenix is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells.
More articles on GI & endoscopy:
FUJIFILM showcases high-resolution imaging innovations and presents next-generation EBUS learning experience at ATS 2016
FUJIFILM showcases comprehensive GI solutions at Digestive Disease Week
FUJIFILM presents double-balloon endoscopy educational presentation at Digestive Disease Week 2016
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.